Insider Transactions in Q1 2021 at Vyne Therapeutics Inc. (VYNE)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,316
-1.32%
|
$37,896
$6.84 P/Share
|
|
Mar 31
2021
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,765
-1.6%
|
$10,590
$6.84 P/Share
|
|
Mar 31
2021
|
Andrew Saik Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
762
-0.67%
|
$4,572
$6.84 P/Share
|
|
Mar 31
2021
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-1.93%
|
$11,670
$6.84 P/Share
|
|
Mar 31
2021
|
Matthew T. Wiley Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,573
-2.2%
|
$15,438
$6.84 P/Share
|
|
Mar 15
2021
|
Patrick G Lepore Director |
BUY
Open market or private purchase
|
Direct |
12,500
+33.33%
|
$87,500
$7.41 P/Share
|
|
Feb 22
2021
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
153,750
+24.27%
|
-
|
|
Feb 22
2021
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
29,213
+20.89%
|
-
|
|
Feb 22
2021
|
Andrew Saik Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,213
+20.37%
|
-
|
|
Feb 22
2021
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
29,213
+22.47%
|
-
|
|
Feb 22
2021
|
Matthew T. Wiley Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,675
+19.13%
|
-
|
|
Jan 28
2021
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
4,219,409
+13.47%
|
$8,438,818
$2.37 P/Share
|